Emily Menendez

GU Oncology Now

Androgen deprivation therapy (ADT) paired with salvage radiation therapy (RT) is known to improve survival for patients with prostate-specific antigen (PSA)-recurrent prostate cancer after radical prostatectomy (RP).Knowing that docetaxel improves survival rates in patients with metastatic hormone-sensitive prostate cancer, Tian Zhang, MD, MHS, and colleagues evaluated a combination of salvage RT, ADT/apalutamide, and docetaxel in the <a href="https://meetinglibrary.asco.org/embargo/record/220519/abstract" target="_blank" rel="noopener">STARTAR phase 2 trial.</a> Results of the trial will be presented at the American Society of Clinical Oncology 2023 Annual Meeting.The multicenter, investigator-initiated, phase 2 trial enrolled 39 patients with recurrent prostate cancer post-RP between March 2018 and February 2020. As of the December 2022 data cutoff, 54% of patients had Gleason 7 prostate cancer, while 46% of patients had Gleason 8 to 10 prostate cancer. The median follow-up was 36 months.Patients were given ADT with apalutamide for 9 months and RT beginning week 8 (66-74 Gy to the prostate bed +/- pelvic lymph nodes over 6-8 weeks). Patients then completed 6 cycles of concurrent docetaxel (75 mg/m2 q3 weeks). The primary end point was 36-month progression-free survival (PFS), defined as a composite of freedom from PSA &gt;0.2 plus post-RT nadir with subsequent rise, clinical progression, other therapy start, or death, among patients with testosterone recovery (&gt;100 ng/dL). Kaplan-Meier estimates for PFS were used to determine landmark 24-month and 36-month rates and were compared with PFS rates from prior trials using a binomial test.Of all patients, 3% were lymph node-positive. The median PSA was 0.58 ng/mL (range, 0.21-3.40), and the median time from RP was 7.6 months (range, 2-98 months). A total of 37 patients (95%) completed at least 1 cycle of docetaxel, while 23 patients (62%) completed all 6 cycles. All patients achieved undetectable PSA nadirs. The PFS rates were 84% at 24 months and 72% at 36 months; 95% of patients recovered testosterone at 36 months. Compared with the 40% historical PFS rate and 53% PFS rate from the STREAM trial, the 72% 36-month PFS rate was statistically significantly improved (P&lt;.001 and P=.013, respectively). Any-grade adverse events included hot flashes, fatigue, alopecia, dysgeusia, rash, and febrile neutropenia.This initial phase 2 trial of ADT, apalutamide, salvage RT, and 6 docetaxel cycles for high-risk PSA recurrence improved the 3-year PFS rate to 72%. Future studies utilizing intensified systemic treatments in the nonmetastatic hormone-sensitive but high-risk salvage setting may be feasible, with fewer patients experiencing cancer progression over time.

The STARTAR Phase 2 Trial: Salvage RT Plus ADT/Apalutamide and Docetaxel

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

Results of the STARTAR phase 2 trial on salvage RT, ADT/apalutamide, and docetaxel were presented at the 2023 ASCO annual meeting.

STARTAR Phase 2 Trial: Salvage RT and Apalutamide, Docetaxel

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe